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Abstract. Thedifferential diagnosis for lymphadenopathy iswide and clinical presentations overlap,making obtaining
an accurate diagnosis challenging. We sought to characterize the clinical and radiological characteristics, histological
ﬁndings, and diagnoses for a cohort of patients with lymphadenopathy of unknown etiology. 121 Peruvian adults with
lymphadenopathy underwent lymph node biopsy for microbiological and histopathological evaluation. Mean patient age
was 41 years (Interquartile Range 26–52), 56% were males, and 39% were HIV positive. Patients reported fever (31%),
weight loss (23%), and headache (22%);HIV infectionwas associatedwith fever (P<0.05) and gastrointestinal symptoms
(P < 0.05). Abnormalities were reported in 40% of chest X-rays (N = 101). Physicians suspected TB in 92 patients (76%),
lymphoma in 19 patients (16%), and othermalignancy in seven patients (5.8%). Histological diagnoses (N = 117) included
tuberculosis (34%), hyperplasia (27%), lymphoma (13%), and nonlymphoma malignancy (14%). Hyperplasia was more
common (P < 0.001) and lymphoma less common (P = 0.005) among HIV-positive than HIV-negative patients. There was
a trend toward reduced frequency of caseous necrosis in samples from HIV-positive than HIV-negative TB patients (67
versus 93%, P = 0.055). The spectrum of diagnoses was broad, and clinical and radiological features correlated poorly
with diagnosis. On the basis of clinical features, physicians over-diagnosed TB, and under-diagnosed malignancy.
Although thismaynot be inappropriate in resource-limited settingswhere TB is themost frequent easily treatable causeof
lymphadenopathy, diagnostic delays can be detrimental to patients with malignancy. It is important that patients with
lymphadenopathy undergo a full diagnostic work-up including sampling for histological evaluation to obtain an accurate
diagnosis.
BACKGROUND
The differential diagnosis for lymphadenopathy is wide and
includes infectious, immunological and metabolic disorders,
and primary or secondary neoplasms.1,2 In the developed
world, common infectious causes predominate including
upper respiratory tract infections, Epstein–Barr Virus, and
cytomegalovirus, whereas in resource-poor settings other
infections such as tuberculosis (TB), toxoplasmosis, HIV se-
roconversion, leishmaniasis, and fungal infections may be
important causes.3 Malignant causes such as lymphoma and
leukemia are less frequent but correct and prompt diagnosis
has prognostic and therapeutic implications. Rarer disorders
such as systemic lupus erythematosus and storage diseases
are also causes of lymphadenopathy. HIV-infected patients
are particularly susceptible to developing hematological ma-
lignancies and to acquiring bacterial, fungal, parasitic, and
viral infections.
The pathophysiology, treatment, and prognosis of the
above conditions differ markedly, and it is therefore crucial to
reach a correct diagnosis for each patient. Diagnostic delays
can be detrimental to patients.4 Few reviews of the clinical and
etiological spectrum of lymphadenopathy in resource poor
countries exist in the recent literature. Herein, we report the
diagnoses and clinical features of a cohort of patients being
investigated for lymphadenopathy in Lima, Peru, and dem-
onstrate the importance of histopathological characterization
of disease.
MATERIALS AND METHODS
Patients were prospectively recruited over a 14-month pe-
riod from the infectious diseases, head and neck surgery, and
general medical and surgical departments of three public
hospitals in Lima, Peru: the Hospital Nacional Dos De Mayo,
Hospital Nacional Daniel Alcides Carrio´n, and Hospital
Nacional Arzobispo Loayza. Lymphadenopathy was deﬁned
as enlargement of one or more lymph nodes. All adult patients
with lymphadenopathy of unknown cause and in whom di-
agnostic lymph node tissue sampling was indicated were
eligible for the study. This was carried out as part of a
prospective evaluation for the accuracy of the Microscopic-
Observation Drug-Susceptibility assay (MODS)5 for the di-
agnosis of lymph node TB, reported elsewhere.6 Ethical
approval was obtained from the Institutional Ethics Committee
of the Universidad Peruana Cayetano Heredia, Asociacio´n
Bene´ﬁcaPRISMA,andeachstudysite’s local ethicscommittee.
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Written informed consent was obtained from all patients. De-
mographicandclinical datawerecollected frompatientsusinga
standardized form. Before the biopsy, the patients’ physician
was asked to predict the most likely diagnosis based on avail-
able clinical information. Tissue sampling procedures and clin-
ical management were undertaken by the hospital clinical staff
with no input from the study team. Where HIV status was not
known, an HIV test was offered.
After sampling, tissue was divided into three parts and un-
derwent histopathological evaluation, microbiological testing
for TB, and standard fungal and bacterial culture. For histo-
pathological assessment, samples were immediately placed
in formaldehyde and transported to the hospital pathology
laboratory where the samples were sealed in parafﬁn blocks
and reported routinely. After completion of enrolment, the
parafﬁn blocks were retrieved and slides for this study were
ﬁxed and stained with hematoxylin–eosin, Ziehl–Neelsen, and
Periodic acid–Schiff (PAS) stains, and analyzed by three pa-
thologists who were blinded to clinical data to minimize bias.
A standardized reporting form was completed on which the
presence or absence of acid-fast bacilli (AFB), granulomas,
and caseating necrosis were recorded, and a diagnosis was
given based on overall assessment. A histological diagnosis
was assigned to the patient when there was concordance
between two or more pathologists. Microbiological testing for
TB comprised Auramine microscopy, Lowenstein–Jensen
culture, and theMODSassay, andmicrobiological criteria for a
TBdiagnosiswere positivity according to oneormore of these
tests. A diagnosis of TB was assigned to patients in whom
histological and/or microbiological criteria were met.
Data were entered into Excel spreadsheets and analyzed
using Stata version 12 (StataCorp, College Station, TX).
Comparisons weremade using Fisher’s exact test for nominal
data and the Mann–Whitney U test for continuous data. A
P < 0.05 was considered signiﬁcant. Agreement between
the pathologists was assessed using Cohen’s Kappa co-
efﬁcient for multiple ratings (κ);κ ³ 0.61 indicates substantial
agreement.7
RESULTS
One hundred and thirty-two patients agreed to partici-
pate in the study and underwent biopsy. Parafﬁn blocks
were retrieved for full histopathological evaluation for 121/
132 (92%) patients. The 11/132 (8.3%) for whom this had
not been possible were excluded from all analyses. There
was no signiﬁcant difference in age, sex, frequency of HIV
positivity, or rate of previous TB between patients who
were included in and those who were excluded from
analysis.
Patient demographics are presented in Table 1. 55% of
the patients were male, and median age was 41 years
(interquartile range [IQR] 26–52 years). HIV status was avail-
able for 109 patients, of whom 47 (43%) were HIV-positive.
Median CD4 count, which was available for 31 patients, was
156 cells/mm3 (IQR 41–277). Seventeen HIV-positive patients
(36%) were taking antiretroviral drugs at the time of biopsy.
HIV-positive patients were more likely than HIV-negative pa-
tients to be male (75% versus 43%, P = 0.001) and were
younger (33 versus 45 years, P = 0.006).
TABLE 1
Patient demographics, clinical characteristics, and radiological features
HIV positive (N = 47) HIV negative (N = 74) P value Total (N = 121)
Patient demographics
Females (%)* 12 (26) 42 (57) 0.001 54 (45)
Age, median years (IQR)† 33 (26–43) 45 (26–62) 0.0063 41 (26–52)
CD4 count, median cells/mm3 (IQR)† 156 (41–277) N/A N/A 156 (41–277)
HIV-positive patients receiving
antiretroviral therapy at time of biopsy (%)*
17/47 (36) 0 1.0 17/47 (36)
Previous TB (%)* 10 (21.3) 11 (14.9) 0.46 21 (17)
Duration of symptoms, months. Median
(IQR)†
3 (1–9) 4 (1.5–12) 0.24 3 (1–12)
Symptom
Fever (%)* 20 (43) 18 (24) 0.045 38 (31)
Weight loss (%)* 13 (28) 15 (20) 0.38 28 (23)
Headache (%)* 11 (23) 15 (20) 0.82 26 (22)
Cough (%)* 11 (23) 11 (15) 0.33 22 (18)
Local pain or tenderness (%)* 5 (11) 15 (20) 0.21 20 (17)
Malaise (%)* 10 (21) 10 (14) 0.32 20 (17)
Appetite loss (%)* 6 (13) 5 (6.8) 0.36 11 (9.1)
Gastrointestinal symptoms (%)* 7 (15) 3 (4,1) 0.045 10 (8.3)
Neck pain (%)* 4 (8.5) 6 (13) 1.000 10 (8.3)
Dyspnea (%)* 6 (13) 2 (4.2) 0.055 8 (6.6)
Asymptomatic (%)* 3 (6.4) 6 (13) 1.0 9 (7.4)
Radiological ﬁndings
CXR normal (%)* 21 (45) 40 (54) 0.35 61 (50)
CXR abnormal (%)* 20 (43) 20 (27) 0.11 40 (33)
Pleural effusion(s) (%)* 4 (8.5) 8 (11) 0.76 12 (9.9)
Pulmonary inﬁltrates and/or
consolidation (%)*
4 (8.5) 7 (9.5) 1.0 11 (9.1)
Hilar and/or paratracheal adenopathy (%)* 2 (4.3) 6 (8.1) 0.48 8 (6.6)
Cavitation (%)* 0 (0) 1 (1.4) 1.0 1 (0.8)
Miliary disease (%)* 0 (0) 1 (1.4) 1.0 1 (0.8)
N/A = not applicable.
* Compared using Fisher’s exact test, 2-tailed.
†Compared using Mann–Whitney U test.
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Data on symptoms at presentation were recorded for 116
(96%) patients (Table 1). The most common presenting
symptoms were fever (N = 38), weight loss (N = 28), headache
(N = 26), cough (N = 22), local pain or tenderness (N = 20),
malaise (N = 20), appetite loss (N = 11), gastrointestinal
symptoms (N = 10), neck pain (N = 10), and dyspnea (N = 8).
Median duration of symptoms fromonset until the lymph node
biopsy was 3 months (IQR 1–12 months). HIV-positive pa-
tients were more likely than HIV-negative patients to report
fever (47% and 24% respectively, P < 0.05) and gastrointes-
tinal symptoms (15% and 4.1% respectively, P < 0.05).
Chest X-rays were available for 101 patients (84%) and ra-
diological abnormalitieswere reported for 40of thesepatients.
Speciﬁc abnormalities included pleural effusion(s) (N = 12),
pulmonary inﬁltrates and/or consolidation (N=11), hilar and/or
paratracheal adenopathy (N = 8), cavitation (N = 1), andmiliary
changes (N = 1). Radiological abnormalities were present in
30% of HIV-positive and 47% of HIV-negative patients (P =
0.087) but therewas no association betweenHIV infection and
any speciﬁc radiological abnormality (Table 1).
A histological diagnosis was reached by agreement
between ³ 2 pathologists for 117 patients (97%, Table 2,
Figure 1). The most common histological diagnoses were TB
(34%, N = 40), reactive hyperplasia (27%, N = 31), lymphoma
(12.8%, N = 15), and other malignancy (14%, N = 16). Inter-
observer agreement between the three pathologists’ di-
agnoses was high, particularly for TB (κ = 0.85), hyperplasia
(κ = 0.64), lymphoma (κ = 0.66), Kaposi’s sarcoma (κ = 0.87),
and other malignancy (κ = 0.88). Of the patients who had a
diagnosis of “other” (N = 11), the tissue sample had been
deemed inadequate or non-lymph node in 8 cases.
Patients with lymphoma were older than patients without
lymphoma (median age 62 versus 38 years, P = 0.0021) and
patients with hyperplasia were more likely to be male than
those with other diagnoses (77% versus 49%, P = 0.011).
Lymph node hyperplasia was more common, and lymphoma
less common, amongHIV-positive thanHIV-negative patients
(P < 0.001 and P = 0.005, respectively). A histological di-
agnosis of lymphoma was associated with headache, which
was reported in 7/15 patients with lymphoma versus 18/102
patients without lymphoma, (P < 0.05). Hyperplasia was as-
sociatedwith fever (16/31 patients with, versus 21/86 patients
without hyperplasia, P = 0.007) and diarrhea (4/31 patients
with, versus 2/86 patients without hyperplasia, P = 0.042).
Patientswith lymphomaor othermalignancywere less likely to
report cough and/or difﬁculty in breathing than patients with
other diagnoses (0/15ptswith, versus 30/102patientswithout
lymphoma, P = 0.011; 8/16 patients with, versus 22/101 pa-
tients without non-lymphoma malignancy, P = 0.028). There
was no association between abnormalities on chest X-ray and
histological diagnosis (data not shown).
Granulomata were observed by ³ 2 pathologists in samples
from 42 patients. One of these patients had Histoplasma
capsulatum detected on both histological analysis and fungal
culture (patientHIVpositivewith aCD4count of 28cells/mm3),
and one patient was assigned a diagnosis of hyperplasia. The
remaining 40 patients were given a histological diagnosis of
TB. Caseous necrosis was observed in samples from 34 pa-
tients; granulomatawere also reported in all 34. Inter-observer
agreement was high for the presence of granulomas and ca-
seous necrosis (κ = 0.83 and 0.90, respectively), but not AFB
(κ = 0.18): AFB were observed on ZN staining by two or more
pathologists in just two specimens, both from HIV-positive
patients. Caseous necrosis tended to be observed less fre-
quently in samples from patients who were HIV-positive than
from those who were HIV-negative (67%,N = 46 versus 93%,
N = 71; P = 0.055). Of 40 patients who were assigned a di-
agnosis of TB according to histological criteria, 31 patients
were also positive according to microbiological criteria. Mi-
crobiological data have been reported in detail elsewhere.6
Eight patients were positive according to microbiological, but
not histological, criteria. These patients had histological di-
agnoses of: hyperplasia (N = 4), lymphoma (N = 1), other
malignancy (N = 1), other diagnosis (N = 1), and no diagnosis
reached by consensus (N = 1). Patients who met histological
but not microbiological criteria for TB weremore likely to have
been treated for TB in the past than those who were also
positive by microscopy and culture (5/9 patients versus 2/31
patients, respectively, P = 0.003).
Clinical diagnoses given by the patients’ physicians prior to
biopsy did not predict histological diagnosis (Figure 1). The
most common clinical diagnosis was TB (N = 92, 76%), in-
cluding for 45/48 patients (94%) who subsequently had a
histological and/ormicrobiological diagnosis of TB and for 47/
73 patients (64%) in whom no evidence of TB was found. TB
was also the most common predicted diagnosis for patients
TABLE 2
Histopathological ﬁndings and diagnoses for HIV-positive and HIV-negative patients in whom ﬁnal diagnosis was reached by consensus by two or
more pathologists (N = 117)
HIV positive (%) (N = 46)
HIV-negative/status unknown (%)
(N = 71) P value* Total (%) (N = 117)
Diagnosis of TB Overall TB diagnosis 16 (35) 31 (44) 0.44 47 (40)
Histological TB diagnosis 12 (26) 28 (39) 0.17 40 (34)
Microbiological TB diagnosis 12 (26) 26 (37) 0.31 38 (33)
Histological diagnosis TB 12 (26) 28 (39) 0.17 40 (34)
Lymphoma 1 (2.2) 14 (20) 0.005 15 (13)
KS 2 (4.4) 1 (1.4) 0.56 3 (2.6)
Other malignancy 3 (6.5) 13 (18) 0.098 16 (14)
Hyperplasia 24 (52) 7 (9.9) < 0.001 31 (27)
Histoplasmosis 1 (2.2) 0 (0) 0.39 1 (0.85)
Other 3 (6.5) 8 (11) 0.52 11 (9.4)
Histological ﬁndings in patients with
histological diagnosis of TB
Acid-fast bacilli 2/12 (17) 0/28 (0) 0.085 2 (1.7)
Granuloma 12/12 (100) 28/28 (100) 1.0 42 (36)
Caseous material 8/12 (67) 26/28 (93) 0.055 34 (29)
*Compared using Fisher’s exact test, 2-tailed.
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with all other histological diagnoses. TB, lymphoma, andother
malignancy together accounted for the majority of clinical
diagnoses (98% of patients), whereas these three condi-
tions comprised less than 50% of histological diagnoses.
Therewas no difference in frequency of clinical diagnosis of
TB or lymphoma according to HIV status (Figure 2). A
clinical diagnosis of nonlymphomatous malignancy was
only given to patients who were HIV negative (7/74 versus
0/47, P = 0.029).
DISCUSSION
This study deﬁned the clinical and histopathological char-
acteristics of a prospective cohort of Peruvian patients with
lymphadenopathy. The spectrum of conditions causing
lymphadenopathy was broad and comprised a mixture of in-
fective, malignant, and benign causes similar to ﬁndings from
caseseries inPeru8and resource-limitedsettingselsewhere.9–14
Clinical characteristics were not speciﬁc in attaining a di-
agnosis. TB was given as the most likely diagnosis in the
majority of the patients (76%), whereas in fact hyperplasia,
lymphoma, and other malignancy each also contributed a
signiﬁcant burden of disease. These ﬁndings highlight the
importance of tissue sampling for histological evaluation
as part of a thorough diagnostic workup.
Clinical presentation was heterogeneous and there was
little relationship between either symptoms or radiological
ﬁndings and diagnosis, even when disaggregated according
toHIV status. Increasing agewasassociatedwithmalignancy,
as in previous reports.15,16 Fever and gastrointestinal symp-
toms were more frequent in HIV positive compared with HIV-
negative patients, but the lowmedian CD4 count in our cohort
of patients means that such symptoms are likely to be mani-
festations of advanced HIV infection itself rather than of a
coexisting disease.
Interobserver concordance was high with respect to histo-
logical features and diagnoses given by the pathologists.
Accuracy of histopathological assessmentmay be dependent
on the skill and experience of the observer, but in clinical
practice may be greater than that observed, since the pa-
thologist is not usually blinded to clinical information but in-
stead interprets observations within a clinical context. AFB
visualization after ZN staining on histopathological analysis
was infrequent compared with rates reported in other se-
ries.8,14,17 AFB detection in ﬁxed tissue specimens is notori-
ously challenging and time-consuming. Although there have
been efforts to devise a classiﬁcation or grading system for
histopathological evaluation of TB lymphadenitis,18 in-
terpretation remains variable and in busy clinical settings
patterns in tissue architecture such as caseous necrosis may
be relied upon more heavily than direct observation of or-
ganisms. Granulomata and caseous necrosis are useful to
diagnose TB but do also occur in fungal diseases,19 which
may be missed as a result. It may thus be useful to carry out
FIGURE 1. Stacked bar chart showing histological diagnoses where a diagnosis was reached by consensus (Total (N = 117), and according to
physicians’ clinical diagnosis). The patients’ physicians were asked to give the most likely diagnosis based on available clinical information only.
Physicians predicted tuberculosis in the majority of patients (N = 90, 77%), lymphoma in 17 patients (15%), other malignancy in seven patients
(6.0%), andgavean alternative diagnosis in 3 patients (2.6%).Histological diagnoses included tuberculosis (N=40, 34%), lymphoma (N=15, 13%),
Kaposi’s sarcoma (N=3, 2.3%), othermalignancy (N=16, 14%), hyperplasia (N=31, 27%), histoplasmosis (N=1, 0.85%), andother diagnoses (N=
11, 9.4%). Clinical diagnoses correlated poorly with histological diagnoses.
FIGURE 2. Stacked bar chart showing presumptive clinical diagnosis given by physicians prior to biopsy, according toHIV status. Nonlymphoma
malignancy was associated with negative HIV status: it was diagnosed clinically in seven HIV-negative patients and in no HIV-positive patients
(P=0.029). HIV status did not affect the frequencyof predicted TB (39/47HIV-positive patients vs 53/74HIV-negativepatients,P=0.19), lymphoma
(6/47 HIV-positive patients vs 13/74 HIV-negative patients, P = 0.61), or other diagnoses (2/47 HIV-positive patients vs 1/74 HIV-negative patients,
P = 0.33).
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additional tests, including PAS and/or Silver staining, when
this is observed to detect fungal causes.
There was some discrepancy between the histopathologi-
cal and microbiological diagnoses of TB, with 31 patients
positive according to both, nine patients positive according to
histological examination only, and eight patients positive
according to microbiological criteria only. An exclusively his-
tological diagnosis was associated with previous episodes of
TB. It is possible that persistent changes in tissue architecture
from previously treated TB may have led to false-positive
diagnoses, and/or that recent use of antibiotics with some
anti-mycobacterial effect may have led to false-negative mi-
crobiological results.20
In practice, itmay be necessary to initiate treatment of some
patients before accurate diagnostic information is available.
An over-estimation of the number of patients with TB by their
physicians, as we found in our cohort, may lead to empirical
anti-TB chemotherapy in a number of patients with other
diseases whilst awaiting test results and/or assessment of
clinical response to treatment. Although this can lead to ad-
verse effects of unnecessary drugs, this strategy may not be
wholly inappropriate as in resource poor settings TB is the
most frequent, easily treatable cause of lymphadenopathy.
The trend seen in our data towards reduced frequency of
caseous necrosis in samples fromHIV positive comparedwith
HIV-negative patients (P = 0.055) is contrary to what was
expected. In pulmonary TB lesions in HIV-positive patients,
poorly formed granulomas with extensive tissue necrosis are
frequently seen.21,22 It is plausible that HIV-positive patients
with severe disease including caseous necrosis may be more
likely to be commenced on anti-TB treatment based on the
results of other investigations, or empirically on clinical
grounds. Such patients would not have undergone lymph
node tissuesamplingand thuswouldnot havebeeneligible for
this study.
A signiﬁcant proportion of the patients within this cohort
were HIV-positive, with a low median CD4 count of 156 cells/
mm3. For many patients, this episode of illness was the ﬁrst
presentation of their HIV, reﬂected in the low proportion of
patients already established on antiretroviral therapy (ART) at
the time of biopsy (36%). The higher rates of hyperplasia ob-
served amongst HIV-positive than HIV-negative patients may
indicate occurrence of the immune reconstitution inﬂamma-
tory syndrome (IRIS), which frequently involves lymph nodes,
in some of the patients taking ART.23 In a retrospective meta-
analysis, 16% of TB/HIV co-infected patients on ART de-
veloped IRIS when TB treatment was commenced, and this
was associated with amortality of 3.2%.24 This association of
a histological diagnosis of hyperplasia with HIV infection is
also likely to account for the increased frequency of fever and
diarrhea found to be associated with hyperplasia. A possible
explanation for the higher frequency of hyperplasia among
HIV-positive patients may be that these patients have an un-
diagnosed pathology. A postmortem study of 16 HIV-positive
patients who died in the Hospital Nacional Dos De Mayo,
Lima, Peru, found that 14 (88%) had at least one AIDS-related
disease that had not been suspected or diagnosed ante-
mortem.25
A signiﬁcant limitation of this study is that patients were
not followed up after the biopsy. Some patients may have
undergone further investigation before a deﬁnitive diagnosis
was reached, and/or their initial diagnosis may have been
revised. A further limitation is that we did not perform sero-
logical testing for other infective causes of lymphadenopathy
such as Epstein–Barr virus, cytomegalovirus, toxoplasmosis,
brucellosis, orCoxiella. It is possible that some of the patients
had these investigations performed outside the study. These
additional tests were not included in our study due to limited
resources, andbecause the focusof themain studywasonTB
diagnostics. Therefore,wemayhavemissed somediagnoses,
or incorrectly ascribed them to hyperplasia, particularly in the
HIV-positive patients.
In summary, this study showed that the spectrum of clinical
diagnoses in Peruvian patients with lymphadenopathy is
broad, and comprises a mixture of infective, malignant, and
benign causes. Clinical manifestations can be highly variable
andare not reliable formakingadiagnosis.When investigating
these patients it is important to perform a full diagnostic
workup. This should include tissue sampling for diagnostic
testing where resources permit. Histological evaluation may
be key in reaching adiagnosis, and should not bedelayed. The
current approach of treating for TB if histology is not available
or is nondiagnostic is pragmatic, but will lead to signiﬁcant
over-treatment with the associated risks of adverse drug
reactions.
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